ClinicalTrials.gov
public full text
Public Domain
Medical Access Program for Patritumab Deruxtecan
The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- NuvOx Expanded Access#1197511
- A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases#980390
- Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)#894516
- Research Study Investigating How Well NDec Works in People With Sickle Cell Disease#878507
- Establishment of a large-scale oral disease registry (NDCS-ODR) in a national specialty center.#354667
Record · ID 1351413
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive